J.B.CHEMICALS & PHARMACEUTICALS LTD.
P&L
Quarterly Consolidated
vs Q1 FY26
JB Pharma Reports 8% Revenue Growth to INR 1085 Crores in Q2 FY26
11 Nov 2025 · 11 Nov 2025, 05:15 pm
Summary
JB Chemicals & Pharmaceuticals Ltd, also known as JB Pharma, has announced its financial results for the quarter ended on September 30, 2025. The company reported an 8% increase in revenue, which stood at INR 1,085 crores. The operating EBITDA increased by 12% to INR 319 crores, and the net profit rose by 19% to INR 208 crores. The growth was driven by the domestic business, which outperformed the market, and the CDMO business, which showed momentum with a solid order book.
Key Highlights
- 1
Revenue growth of 8% to INR 1085 crores
- 2
Operating EBITDA increased by 12% to INR 319 crores
- 3
Net Profit increases by 19% to INR 208 crores
- 4
Domestic business outperformed the market
- 5
CDMO business showed momentum with a solid order book
Management Comments
Mr. Nikhil Chopra
JB’s domestic business continued to outperform the market, with all major brands delivering robust growth. Our focus on driving steady volume growth across key brands — including recently acquired portfolios — continues to yield good results. On the international front, momentum in our CDMO business has returned, supported by a solid order book that positions us for further growth in the second half of the year.
Informational and educational content only. Not investment advice.